ClinicalTrials.gg

Program

Eflornithine

Also written as “DFMO”, “Eflornithine (Dose Level 1)” and “Eflornithine (Dose Level 2)”.

Its studies are mostly in Adenomatous Polyposis Coli · Melanoma · Glioblastoma · Astrocytoma · Hirsutism, led by 4 companies.

Furthest: phase 4, since Nov 19, 20107 company-led studies, 2 open or runningNext primary completion: Feb 28, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Cancer Prevention Pharmaceuticals30 open or runningphase 3since Nov 19, 2010Nov 19, 2010none ahead
Orbus Therapeutics21 open or runningphase 3since Jun 3, 2016Jun 3, 2016none ahead
AbbVie10 open or runningphase 4since Sep 8, 2005Sep 8, 2005none ahead
Aminex Therapeutics11 open or runningphase 2since Nov 24, 2025Nov 24, 2025Feb 28, 2028phase 2 · NCT07287917

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 8, 2005First study: phase 4 study in HirsutismNew to AbbVieAbbVie · NCT00152048 · 78 enrolled
  2. Nov 19, 2010Cancer Prevention Pharmaceuticals's first study: phase 3 study in Adenomatous Polyposis ColiNew to Cancer Prevention PharmaceuticalsCancer Prevention Pharmaceuticals · NCT01245816
  3. Nov 21, 2011Phase 3 study in Adenomatous Polyposis ColiCancer Prevention Pharmaceuticals · NCT01483144 · 171 enrolled · United States, Belgium, Canada and more
  4. Jul 2, 2012Phase 2 study in NeoplasmsCancer Prevention Pharmaceuticals · NCT01636128
  5. Jun 3, 2016Orbus Therapeutics's first study: phase 3 study in AstrocytomaNew to Orbus TherapeuticsOrbus Therapeutics · NCT02796261 · 343 enrolled · United States, Belgium, Canada and more
  6. May 3, 2023Phase 1 study in GlioblastomaOrbus Therapeutics · NCT05879367 · 66 planned · United States
  7. Nov 24, 2025Aminex Therapeutics's first study: phase 2 study in MelanomaNew to Aminex TherapeuticsAminex Therapeutics · NCT07287917 · 92 planned · United States

Ahead

  1. Feb 28, 2028Primary completion: phase 2 study in MelanomaAminex Therapeutics · NCT07287917

TargetBeta

ODC1 →read by rule
“Ornithine decarboxylase inhibitor”ChEMBL 37, by rule

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07287917Melanoma · United States2RecruitingAminex TherapeuticsFeb 28, 202892
NCT05879367Glioblastoma · United States1RecruitingOrbus TherapeuticsJun 30, 202666
NCT02796261Astrocytoma · United States, Belgium, Canada and more3UNKNOWNOrbus TherapeuticsJun 2023343
NCT01636128Neoplasms2WithdrawnCancer Prevention PharmaceuticalsMar 20160
NCT01483144Adenomatous Polyposis Coli · United States, Belgium, Canada and more3CompletedCancer Prevention PharmaceuticalsNov 2018171
NCT01245816Adenomatous Polyposis Coli3WithdrawnCancer Prevention PharmaceuticalsMay 20130
NCT00152048Hirsutism4CompletedAbbVie78

How it is read

Names in the registry

  • “Eflornithine”, 2 entries
  • “DFMO”, 1 entry
  • “Eflornithine (Dose Level 1)”, 1 entry
  • “Eflornithine (Dose Level 2)”, 1 entry
  • “Eflornithine (Dose Level -1)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.